title: Combination Ointment Containing Solid Tranilast Nanoparticles and Dissolved Sericin Is Efficacious for Treating Skin Wound-Healing Deficits and Redness in Diabetic Rats.
abstract: We attempted to design a combination ointment containing solid tranilast nanoparticles and dissolved sericin as a wound-healing drug (TS-combination ointment), and evaluated its usefulness as therapy for wound-healing deficits in streptozotocin-induced diabetic rat (STZ rat) using kinetic analyses as an index. Solid tranilast nanoparticles were prepared by bead mill methods with low-substituted methylcellulose; the mean particle size of the tranilast nanoparticles was 70 nm. The ointment was designed to contain the tranilast nanoparticles plus sericin powder and/or Carbopol®934. Skin wound healing in STZ rats begins significantly later than in normal rats. Although the skin wound healing rate in STZ rats treated with an ointment containing tranilast nanoparticles was lower than in STZ rats treated with vehicle, the ointment was effective in reducing redness. An ointment containing sericin enhanced the skin-healing rate, but the preventive effect on redness was weak. On the other hand, the combination of tranilast and sericin increased both the skin healing rate and reduction in redness. In conclusion, we have adapted kinetic analyses to skin wound healing in rats, and found these analyses to be useful as an index of wound healing ability by a wound-healing drug. In addition, we show that treatment with the TS-combination ointment enhances the skin wound healing rate and reduces redness. These findings provide information significant to the search for new wound-healing therapies and for the design of wound-healing drugs.
authors.affiliation: Faculty of Pharmacy, Kindai University.
authors.forename: Noriaki
authors.initials: N
authors.lastname: Nagai
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Ogata
authors.forename: Saori
authors.initials: S
authors.lastname: Deguchi
authors.forename: Akina
authors.initials: A
authors.lastname: Ueno
authors.forename: Naohito
authors.initials: N
authors.lastname: Kawasaki
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Ito
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D008297:Male; D053758:Nanoparticles / Q000008:administration & dosage*; D009824:Ointments; D051381:Rats; D017208:Rats, Wistar; D047030:Sericins / Q000008:administration & dosage*; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology; D062367:ortho-Aminobenzoates / Q000008:administration & dosage*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D009824:Ointments; D047030:Sericins; D062367:ortho-Aminobenzoates; C012293:tranilast